Ablynx Announces Warrant Exercise

Ablynx Announces Warrant Exercise 
Regulated Information 
GHENT, BELGIUM -- (Marketwire) -- 01/21/13 --  Ablynx (EURONEXT
BRUSSELS: ABLX) today announced, in conformity with Title II of the
Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an
additional 61,812 common shares have been issued by the Company in
exchange for EUR 329,619.51 as the result of the exercise of warrants
by some employees and consultants of the Company. 
As a result of this transaction, Ablynx now has 43,779,197 shares
outstanding. 
About Ablynx
 Ablynx is a biopharmaceutical company engaged in the
discovery and development of Nanobodies(R), a novel class of
therapeutic proteins based on single-domain antibody fragments, for a
range of serious human diseases, including inflammation, haematology,
oncology and pulmonary disease. Today, the Company has approximately
25 programmes in the pipeline and five Nanobodies at clinical
development stage. Ablynx has ongoing research collaborations and
significant partnerships with major pharmaceutical companies
including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co.
The Company is headquartered in Ghent, Belgium. More information can
be found on www.ablynx.com. 
Press release (PDF): http://hugin.info/137912/R/1671922/543522.pdf  
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com 
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03 
e: marieke.vermeersch@ablynx.com 
Follow us on Twitter @AblynxABLX 
M:Communications:
Mary-Jane Elliott
Amber Bielecka
Claire Dickinson
t: +44 207 920 2330
e: ablynx@mcomgroup.com